Patient‐reported outcomes from two randomised studies comparing once‐weekly application of amorolfine 5% nail lacquer to other methods of topical treatment in distal and lateral subungual onychomycosis

Abstract

SummaryPatient adherence is a key consideration in the choice of a topical regimen for the treatment of onychomycosis. The objective of this study was to investigate patientreported outcomes (treatment utilisation, adherence and satisfaction) in onychomycosis treated with once-weekly amorolfine 5% nail lacquer versus once-daily ciclopirox 8% nail lacquer (Study A) or once-daily urea 40% ointment/bifonazole 1% cream combination regimen (Study B). Study A: Subjects received amorolfine and ciclopirox on opposite feet for 12 weeks. Study B: Subjects received amorolfine and urea/bifonazole on opposite feet for 6-7 weeks. Assessments included subject adherence as per label, treatment preference and questionnaire. Study A: More subjects adhered to amorolfine (85%) than to ciclopirox (60%) (P = .025). Overall, subjects were satisfied (95% vs 100%, respectively) and the treatments were balanced in terms of preference (50% vs 45%) at week 12. Study B: More subjects adhered to amorolfine dosage (81.8%) than to the dosage of the urea/bifonazole combination regimen (59.1%) (P = .096). At the end of study, 85.7% of subjects preferred amorolfine versus 14.3% for urea/bifonazole. Fewer subjects experienced local side effects with amorolfine (4.5%) compared to urea (27.3%) and bifonazole (15%). Amorolfine 5% nail lacquer offers a simple and convenient treatment option, which may result in improved patient adherence and consequently lead to improved efficacy and patient satisfaction. K E Y W O R D Samorolfine 5% nail lacquer, ciclopirox 8% nail lacquer, onychomycosis, patient adherence, patient-reported outcomes, urea 40% ointment/bifonazole 1% cream

<p>Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia</p>

“…Further, patient preference can have an impact on treatment adherence, which contributes to treatment outcomes. [11][12][13] Therefore, when making treatment decisions, it is important for healthcare providers to not only consider safety and efficacy, but also other treatment attributes that may affect patient preference.…”

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)

“…Furthermore, patient preference can have an impact on treatment adherence, which contributes to treatment outcomes. [3][4][5][6][7][8][9] Therefore, when making treatment decisions for patients with T2D, it is important to consider not only efficacy and safety, but also other treatment attributes which have an impact on patient preference.…”

Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy

“…In patients with diabetes, treatment process attributes, including features of injectable medication, have been shown to influence patient preference [3][4][5][6][7]. Treatment preference and satisfaction are important factors because they can contribute to treatment adherence, which could affect health outcomes [4,[7][8][9][10][11][12][13]. Furthermore, guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) highlight the importance of considering patient preference when choosing treatments for patients with diabetes [14].…”